journal article·2024-12-11

STING Nanoagonist Boosts Antitumor Immunity of Therapeutic DNA Vaccines

Wencong Jia, Janin Chandra, Siok Min Teoh, Lynn Tolley, Haotian Yang, Brian W. C. Tse, Kamil A. Sokolowski, Xiaowen Liang, Darrell H. G. Crawford, Jason C. Steel, Chengzhong Yu, Michael S. Roberts, Ian H. Frazer, Yu Chen, Haolu Wang, Meihua Yu

Nano Letters· Volume 24· Issue 49
Publisher page

Abstract

Therapeutic DNA cancer vaccines can stimulate specific immune responses against cancer antigens but often induce suboptimal therapeutic responses. Here, we demonstrate that a manganese-doped silica nanoparticle STING agonist (MSNA) enhances the immune response of plasmid DNA vaccines, promoting the activation and migration of distinct subsets of dendritic cell (DC) and improving antitumor immunity in three animal models. MSNA coadministered with an α-fetoprotein (AFP) encoded plasmid DNA (AFP-DNA) elicited significantly higher AFP-specific CD8 T cell responses than free AFP-DNA. Animals immunized with MSNA-AFP-DNA remained tumor-free in an AFP expressing hepatocellular carcinoma challenge model. MSNA combined with a DNA plasmid encoding the human papillomavirus type 16 oncoproteins E6 and E7 induced potent E7-specific CD8 T cell responses, preventing the growth of E7-expressing solid TC-1 tumors and promoting the shrinkage of E7-expressing skin grafts. These findings together demonstrate that coadministration of MSNA can improve the efficacy of therapeutic DNA vaccines targeting cancer-specific antigens.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Immunotherapy and Immune Responses · interferon and immune responses · Virus-based gene therapy research

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Materdicine Lab, School of Life Sciences, Shanghai University, Shanghai 200444, China

School of Medicine, Shanghai University, Shanghai 200444, China

Frazer Institute, Faculty of Medicine, The University of Queensland, Woolloongabba, Queensland 4102, Australia

Gallipoli Medical Research, Greenslopes Private Hospital, Brisbane, Queensland 4120 Australia

Faculty of Medicine, The University of Queensland, Brisbane, Queensland 4006 Australia

Preclinical Imaging Facility, Translational Research Institute, Woolloongabba, Queensland 4102, Australia

School of Health, Medical and Applied Sciences, CQUniversity, North Rockhampton, Queensland 4702, Australia

Australian Institute for Bioengineering and Nanotechnology, The University of Queensland, Brisbane, Queensland 4072, Australia

Clinical and Health Sciences, University of South Australia, Adelaide, South Australia 5000, Australia

Internal Medicine Services, The Prince Charles Hospital, Chermside, Queensland 4032, Australia

Funding

National Health and Medical Research Council · Australian Research Council · Science and Technology Commission of Shanghai Municipality · National Natural Science Foundation of China · Garnett Passe and Rodney Williams Memorial Foundation · University of Queensland · Chinese Academy of Sciences · Shanghai Shuguang Program · School of Medicine, Shanghai University · Shanghai Excellent Overseas Young Scientists · Queensland Biomedical Assistance Fund · Merchant Foundation and the Metal Manufacturing Pty Ltd · Gallipoli Medical Research · Zelman Cowan Academic Initiative

References (35)

Show source-provided references
1. 10.1016/j.cell.2017.01.01610.1016/j.cell.2017.01.016 ↗
2. 10.1038/nrc79810.1038/nrc798 ↗
3. Vollmer C. M. · Cancer Res. · 1999 · 59 · 3064
4. Southgate, T. D.; Stern, P. L. Oncofetal Antigen. In Encyclopedia of Cancer; Schwab, M., Ed. Springer Berlin Heidelberg, 2009; pp 2154–2156.10.1007/978-3-540-47648-1_4219 ↗
5. 10.1126/science.845630210.1126/science.8456302 ↗
6. 10.1038/d41587-021-00023-510.1038/d41587-021-00023-5 ↗
7. 10.4161/21645515.2014.98068610.4161/21645515.2014.980686 ↗
8. 10.1038/s41591-024-02894-y10.1038/s41591-024-02894-y ↗
9. 10.1021/acs.nanolett.4c0139210.1021/acs.nanolett.4c01392 ↗
10. 10.15252/emmm.20221683610.15252/emmm.202216836 ↗
11. 10.1002/adhm.20220292110.1002/adhm.202202921 ↗
12. 10.1007/s10853-020-05660-w10.1007/s10853-020-05660-w ↗
13. 10.1002/EXP.2021015710.1002/EXP.20210157 ↗
14. 10.1637/0005-2086(2007)51[573:DVOTAC]2.0.CO;210.1637/0005-2086(2007)51[573:DVOTAC]2.0.CO;2 ↗
15. 10.3892/mmr.2012.107910.3892/mmr.2012.1079 ↗
16. 10.1038/nature0847610.1038/nature08476 ↗
17. 10.4049/jimmunol.150183610.4049/jimmunol.1501836 ↗
18. 10.1038/nature0653710.1038/nature06537 ↗
19. 10.1038/sj.gt.330180910.1038/sj.gt.3301809 ↗
20. 10.1016/j.immuni.2018.03.01710.1016/j.immuni.2018.03.017 ↗
21. 10.1038/s41565-022-01225-x10.1038/s41565-022-01225-x ↗
22. 10.1038/s41565-023-01447-710.1038/s41565-023-01447-7 ↗
23. 10.4049/jimmunol.200035510.4049/jimmunol.2000355 ↗
24. 10.1002/adma.20240258010.1002/adma.202402580 ↗
25. 10.1006/mthe.2001.046510.1006/mthe.2001.0465 ↗
26. 10.2471/BLT.10.07942610.2471/BLT.10.079426 ↗
27. 10.1038/s41577-018-0088-110.1038/s41577-018-0088-1 ↗
28. 10.1038/s41577-019-0210-z10.1038/s41577-019-0210-z ↗
29. 10.1038/nri210310.1038/nri2103 ↗
30. 10.1038/s41392-023-01547-910.1038/s41392-023-01547-9 ↗
31. 10.1002/hep.2689310.1002/hep.26893 ↗
32. 10.1097/CJI.000000000000015610.1097/CJI.0000000000000156 ↗
33. 10.1007/s00262-020-02720-710.1007/s00262-020-02720-7 ↗
34. 10.3389/fonc.2024.141925810.3389/fonc.2024.1419258 ↗
35. 10.1006/viro.1997.865010.1006/viro.1997.8650 ↗